Vistagen Therapeutics, Inc. VTGN

Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup analysis.

Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orle

Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months PALISADE-4 OLE data add to growing body of evidence supporting fasedienol’s potential to address social anxiety disorder in anxiety-provoking social and performance situations in everyday

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorderSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Ph

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned during the current quarter regarding potential future Phase 3 path forward for fasedienol in social anxiety disorder Appointments of Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D. to the Board add decades of neuroscience drug development experience SOUTH SAN FRANCI

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCI

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:SRXH) acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN).

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop a

Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategySOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Bo

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety […]

SOUTH SAN FRANCISCO, Calif., June 30, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder.